EGFR-targeting drugs in combination with cytotoxic agents: From bench to bedside, a contrasted reality

British Journal of Cancer

Volumn 99, Issue 1, 2008, Pages 1-5

  Milano, G ^a   Spano, J P ^b   Leyland Jones, B ^c  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bench to bedside; Combination; Cytotoxic agents; EGFR targeting drugs

Indexed keywords

CEDIRANIB; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; TAXANE DERIVATIVE; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; COLORECTAL CANCER; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HEAD AND NECK CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SHORT SURVEY;

ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 46349097694     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604373     Document Type: Short Survey

References (47)

1. Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C (2005) In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 1: 1-10
2. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R (1998) Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273: 1568-1573
3. Baselga J (2001) The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 37: S16-S22
4. Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7: 2-8
5. Baselga J (2004) Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 22: 759-761
6. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A (2005) Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23: 5568-5577
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 9: 567-578
8. Bonomi PD, Buckingham L, Coon J (2007) Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 13: s4606-s4612
9. Bozec A, Formento P, Lassalle S, Lippens C, Hofman P, Milano G (2007) Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 97: 65-72
10. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magné N, Milano G (2004) Pharmacological background of EGFR targeting. Ann Oncol 15: 1007-1012
11. Chou TC, Talalay P (1984) Quantitative analysis of dose - effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
12. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK (2006) Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 66: 981-988
13. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G (2000a) Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6: 3739-3747
14. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G (2000b) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063
15. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer. N Engl J Med 351: 337-345
16. Davies AM, Ho C, Lara PN, Mack P, Gumerlock PH, Gandara DR (2006) Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 7: 385-388
17. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa F, Mueller B, Von Pawel J (2004) Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 22(Suppl): 617s
18. Gieseg MA, de Bock C, Ferguson LR, Denny WA (2001) Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs 12: 683-690
19. Harari PM, Allen GW, Bonner JA (2007) Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25: 4057-4065
20. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA, TRIBUTE Investigator Group (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892-5899
21. Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, Linn M, Wheeldon E, Gand L, Birnboeck H, Hoffmann G (2004) Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15: 503-512
22. Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166-2174
23. Huang SM, Li J, Armstrong EA, Harari PM (2002) Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62: 4300-4306
24. Kassouf W, Luongo T, Brown G, Adam L, Dinney CP (2006) Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 176: 787-792
25. Kedar D, Baker CH, Killion JJ, Dinney CP, Fidler IJ (2002) Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 8: 3592-3600
26. 1 arrest in oral squamous carcinoma cell lines. Oncology 63: 92-98
27. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379
28. 1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 72: 248-258
29. Magné N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, Milano G (2002) Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86: 819-827
30. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385
31. Moore MJ (2005) Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol 32: 5-6
32. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, Eckhardt SG, Pepe S, Tortora G, Ciardiello F (2005) Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 16: iv61-iv68
33. Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S (2006) BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 58: 594-600
34. Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'reilly MS, Fidler IJ, Herbst RS (2004) Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Clin Cancer Res 10: 8613-8619
35. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65: 1485-1495
36. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994-1003
37. Sirotnak FM, Zakowsk MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenogafts is markedly enhanced by coadministration of ZDI839 (Iressa), an inhibitor of EGFR tryosine kinase. Clin Cancer Res 6: 4885-4892
38. Smith JA, Gaikwad A, Yu J, Wolf JK, Brown J, Ramondetta LM, Stewart CF (2008) In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines. Cancer Chemother Pharmacol 62: 51-58
39. Solit DB, She Y, Lobo J, Kris MG, Scher HI, Rosen N, Sirotnak FM (2005) Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 11: 1983-1989
40. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ, Gilbertson R, Germain GS, Harwood FC, Houghton PJ (2004) Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64: 7491-7499
41. Tortora G, Caputo R, Damiano V, Fontanini G, Melisi D, Veneziani BM, Zunino F, Bianco AR, Ciardiello F (2001) Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res 7: 4156-4163
42. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P (2005) Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 11: 7480-7489
43. Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG (2006) Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 5: 1154-1165
44. Wild R, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S, Luo F, Camuso A, McGlinchey K, Rose WC (2006) Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther 5: 104-113
45. Xu JM, Azzariti A, Severino M, Lu B, Colucci G, Paradiso A (2003a) Characterization of sequence-dependent synergy between ZD1839 and oxaliplatin. Biochem Pharmacol 66: 551-563
46. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC (2005) Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65: 6943-6949
47. Zhu BD, Yuan SJ, Zhao QC, Li X, Li Y, Lu QY (2005) Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. World J Gastroenterol 11: 1382-1386